Figure 3From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesOverall survival. Symbols on the plot indicate censored patients. Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.Back to article page